Cardiology Cardiovascular Interventions Articles & Analysis
6 articles found
Advancements in medical technology have transformed healthcare, with radiopaque marker bands playing a crucial role in modern medical devices. These small components enhance precision and visibility during medical procedures and have become a key part of catheter designs, improving accuracy and efficiency. Edgetech Industries, a leading radiopaque marker bands manufacturer, provides high-quality ...
Marker bands serve a critical function in medical imaging and interventional procedures, offering Marker bands are essential for precise visualization during medical treatments. Designed for visibility under fluoroscopic imaging, these radiopaque bands, made from materials like platinum-iridium alloy, gold, and tantalum, play a critical role in healthcare applications. They enhance accuracy in ...
In the dynamic landscape of modern medicine, technological advancements continuously reshape diagnostic and therapeutic approaches, fostering innovation and improving patient outcomes. Within this realm, the adoption of fluorinated ethylene propylene (FEP) and perfluoroalkoxy (PFA) tubing has emerged as a game-changer, revolutionizing various medical procedures across diverse specialties. Let's ...
TAILOR-PCI was a 7-year 5,300-patient clinical trial of precision medicine for cardiac stent patients, funded by Mayo Clinic and the National Institutes of Health (NIH). Genomadix’s FDA-cleared rapid RX CYP2C19 genotyping test was used to personalize antiplatelet therapy with clopidogrel or ticagrelor. The results were published on August 25, 2020 in the Journal of the American Medical ...
Genomadix’s European Scientific Advisory Board Comments on TAILOR-PCI Results *The largest genetics-based clinical trial in cardiology history supported by Genomadix’s Precision Medicine technology * The results of the TAILOR-PCI trial (Tailored Antiplatelet Initiation to Lessen Outcomes Due to Decreased Clopidogrel Response after Percutaneous Coronary Intervention) were recently ...
After seven years and 5,300-patients tested, the results of the landmark TAILOR-PCI trial were announced in a virtual ACC session. This trial investigated whether a prospective approach using rapid on-site CYP2C19 testing could improve patient outcomes when selecting P2Y12 inhibitor therapy following PCI procedure. This is based on the well-established evidence that approximately 30-50% of ...